Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32880601

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2020 Oct 1
First author
Shitara K

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2020 Oct 1;6(10):1539-1541. doi: 10.1001/jamaoncol.2020.2436.
    note
    Source null
    related pmid
    32880639
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2021 Apr 1;7(4):632-633. doi: 10.1001/jamaoncol.2020.8002.
    note
    Source null
    related pmid
    33538772
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2021 Apr 1;7(4):633. doi: 10.1001/jamaoncol.2020.8011.
    note
    Source null
    related pmid
    33538773
    relationship
    Comment in

Authors and identifiers

  1. name
    Shitara K
    type
    Author
  2. name
    Van Cutsem E
    type
    Author
  3. name
    Bang YJ
    type
    Author
  4. name
    Fuchs C
    type
    Author
  5. name
    Wyrwicz L
    type
    Author
  6. name
    Lee KW
    type
    Author
  7. name
    Kudaba I
    type
    Author
  8. name
    Garrido M
    type
    Author
  9. name
    Chung HC
    type
    Author
  10. name
    Lee J
    type
    Author
  11. name
    Castro HR
    type
    Author
  12. name
    Mansoor W
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Shitara K
    type
    Author
  2. name
    Van Cutsem E
    type
    Author
  3. name
    Bang YJ
    type
    Author
  4. name
    Fuchs C
    type
    Author
  5. name
    Wyrwicz L
    type
    Author
  6. name
    Lee KW
    type
    Author
  7. name
    Kudaba I
    type
    Author
  8. name
    Garrido M
    type
    Author
  9. name
    Chung HC
    type
    Author
  10. name
    Lee J
    type
    Author
  11. name
    Castro HR
    type
    Author
  12. name
    Mansoor W
    type
    Author
bibliography ids
  1. nci-bib-73894fcecb246af096cef0c9
book metadata
content sha256
d77a42149e542b105e7566d8d561080707ff323014c2e2ec3a4b2c0f14f9bc7f
document type
citation
dois
  1. 10.1001/jamaoncol.2020.3370
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:32880601
immutable id
pubmed:32880601@d77a42149e542b105e7566d8d561080707ff323014c2e2ec3a4b2c0f14f9bc7f
journal
abbreviation
JAMA Oncol
issn electronic
2374-2445
issn print
2374-2437
issue
10
name
JAMA oncology
nlm unique id
101652861
pages
1571-1580
volume
6
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    JAMA Oncol. 2020 Oct 1;6(10):1539-1541. doi: 10.1001/jamaoncol.2020.2436.
    note
    Source null
    related pmid
    32880639
    relationship
    Comment in
  2. citation
    JAMA Oncol. 2021 Apr 1;7(4):632-633. doi: 10.1001/jamaoncol.2020.8002.
    note
    Source null
    related pmid
    33538772
    relationship
    Comment in
  3. citation
    JAMA Oncol. 2021 Apr 1;7(4):633. doi: 10.1001/jamaoncol.2020.8011.
    note
    Source null
    related pmid
    33538773
    relationship
    Comment in
outcomes validated
false
pmid
32880601
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
dfd0a54da6f1748c39603ed5a49921e1dd3aa8b517776ab7c99b0dfb5cba5c8e
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Oct 1
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32880601/
title
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Preserved source evidence · Not medical advice